Evolent Health’s (EVH) Outperform Rating Reiterated at Royal Bank of Canada

Evolent Health (NYSE:EVH)‘s stock had its “outperform” rating reaffirmed by Royal Bank of Canada in a research note issued on Tuesday,Benzinga reports. They currently have a $20.00 target price on the technology company’s stock. Royal Bank of Canada’s price target suggests a potential upside of 56.99% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Barclays cut their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday. Oppenheimer dropped their target price on shares of Evolent Health from $45.00 to $34.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. KeyCorp started coverage on shares of Evolent Health in a report on Friday, October 11th. They issued an “overweight” rating and a $35.00 target price on the stock. Citigroup dropped their target price on shares of Evolent Health from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Finally, JMP Securities dropped their target price on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Evolent Health currently has an average rating of “Buy” and an average target price of $29.50.

Evolent Health Trading Down 11.8 %

Shares of NYSE:EVH opened at $12.74 on Tuesday. The company’s 50-day moving average price is $25.82 and its two-hundred day moving average price is $24.53. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.08. Evolent Health has a one year low of $12.37 and a one year high of $35.00. The stock has a market capitalization of $1.48 billion, a PE ratio of -14.00 and a beta of 1.58.

Insiders Place Their Bets

In other Evolent Health news, CEO Seth Blackley sold 187,904 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the transaction, the chief executive officer now owns 411,924 shares in the company, valued at $12,357,720. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, General Counsel Jonathan Weinberg sold 42,140 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $31.20, for a total transaction of $1,314,768.00. Following the sale, the general counsel now owns 167,027 shares in the company, valued at approximately $5,211,242.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Seth Blackley sold 187,904 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the sale, the chief executive officer now owns 411,924 shares in the company, valued at $12,357,720. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 307,291 shares of company stock worth $9,290,385 in the last quarter. Corporate insiders own 1.60% of the company’s stock.

Institutional Trading of Evolent Health

Several large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its position in shares of Evolent Health by 150.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,469 shares of the technology company’s stock worth $720,000 after acquiring an additional 15,299 shares in the last quarter. Qsemble Capital Management LP acquired a new stake in shares of Evolent Health during the 3rd quarter worth approximately $829,000. Algert Global LLC lifted its stake in Evolent Health by 120.2% in the 3rd quarter. Algert Global LLC now owns 23,025 shares of the technology company’s stock valued at $651,000 after purchasing an additional 12,570 shares during the last quarter. Foundry Partners LLC bought a new position in Evolent Health in the 3rd quarter valued at approximately $10,042,000. Finally, Intech Investment Management LLC bought a new position in Evolent Health in the 3rd quarter valued at approximately $989,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.